Kamada Ltd. · NASDAQ:KMDA
Kamada — Investor Presentation (November 2023)
16 slides from Kamada's investor presentation, Nov 13, 2023
Slide 1: Investors Meeting NASDAQ & TASE: KMDA November 2023
INVESTORS MEETING NASDAQ & TASE: KMDA November 2023
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials .
Slide 3: Kamada Highlights
6 FDA approved products ; global commercial network selling in over 30 countries 2023 revenues guidance of $138M - $146M; Adjusted EBITDA of $22M - $26M; rapidly growing; positive cash - flow; strong balance sheet Multiple growth drivers with limited downside ri sk and significant upside potential K
Slide 4: Financial Growth Trajectory
FINANCIAL GROWTH TRAJECTORY Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses 4 104 129 138 - 146 2021 2022 2023 Revenues US$M 6 18 22 - 26 2021 2022 2023
Slide 5: KEDRAB Anti-Rabies Immune Globulin
o Product launched in the U.S in 2018 in collaboration with Kedrion o Total U.S market size > $150M o Only anti - Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB Anti - Rabies Immune Globulin 12 16 18 12 16 16 31 24 25 36 10 % 20 % 23 % 27 % 32 % 0%
Slide 6: $60M Strategic Investment by FIMI
$60M STRATEGIC INVESTMENT BY FIMI 6 Kamada / November 2023 o Proceeds from the private placement are expected to be used to accelerate the growth of the Company’s existing business and execution of strategic business development opportunities o Approximately 12.6 million ordinary shares at a price o
Slide 7: FDA-Approved Speciality Plasma Products; Key Focus on Transplantation & Rare Conditions
FDA - APPROVED S PECIALITY PLASMA PRODUCTS; KEY FOCUS ON TRANSPLANTATION & RARE CONDITIONS KEDRAB/KAMRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin Intravenous (Human)] Prophylaxis of cytomegalovirus disease associated wi
Slide 8: CYTOGAM CMV Immune Globulin
CYTOGAM is the only plasma - derived IgG approved in the US and Canada for its indication o Indicated for prophylaxis of CMV disease in kidney, lung, liver, pancreas, heart and heart / lung transplants, an area of significant unmet medical need. International guidelines for the management of CMV in
Slide 9: Strategic Entry into the U.S. Plasma Collection Market
STRATEGIC ENTRY INTO THE U.S. PLASMA COLLECTION MARKET 9 Kamada / November 2023
Slide 10: Strategic Entry into the U.S. Plasma Collection Market
STRATEGIC ENTRY INTO THE U.S. PLASMA COLLECTION MARKET Kamada Plasma was established in Q1 20 21 through the acquisition of an FDA - licensed plasma collection center in Texas, focusing on collecting hyper - immune plasma for specialty IgG’s o Strategic transaction which advances Kamad a ’s objectiv
Slide 11: Inhaled AAT for Alpha-1 Antitrypsin Deficiency
o Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC o The leading new innovative AATD treatment in advanced clinical stage (Ph - 3) o Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the
Slide 12: Recently Appointed Independent Directors
RECENTLY APPOINTED INDEPENDENT DIRECTORS 12 Kamada / November 2023 Prof . Benjamin Dekel currently serves as the Founder and Chief Scientist of RenoVate Biopharmaceuticals Ltd . , as director at Sagol Center for Regenerative Medicine, Tel Aviv University ; as Vice - Dean, School of Medicine, Tel Avi
Slide 13: 9M & Q3 Summary Financial Data
9M & Q3 SUMMARY FINANCIAL DATA 13 Kamada / November 2023 Details Q3/ 20 22 Q3/2023 9M/ 20 22 9M/2023 US $ M 25.6 31.4 67.2 86.4 PROPRIETARY 6.6 6.5 16.7 19.7 DISTRIBUTION 26% and 18% YoY increase for 9M & Q3, respectively 32.2 37.9 83.9 106.1 TOTAL REVENUES 12.9 14.8 31.4 41.1 GROSS PROFIT 40% 39% 3
Slide 14: Kamada Investment Highlights
KAMADA INVESTMENT HIGHLIGHTS 14 Kamada / November 2023 A global leader; focused on areas of limited treatment alternatives Financially stable; profitable; cash - generating; continued double digit growth 6 FDA approved products with significant worldwide growth potential Leading innovative product f
Slide 15: Thank You
November 202 3 THANK YOU WWW.KAMADA.COM
Slide 16: Non-IFRS Measures – Adjusted EBITDA
Non - IFRS measures – Adjusted EBITDA Q3/ 20 22 Q3/2023 9M/ 20 22 9M/2023 US $ M 0.5 3.2 (5.3) 3.2 Net loss 0.0 0.1 0.1 0.2 Taxes on income 2.0 1.3 5.9 3.4 Revaluation of Acquisition related contingent consideration 0.0 (0.2) (0.2) 0.5 Other financial expense, net 1.8 1.8 5.3 5.3 Amortization of acq